Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events (NASDAQ:ARWR)
· seekingalpha.com
Arrowhead (ARWR) Q3 2026 earnings call: SHASTA-3/4 Phase III sHTG wins, PRV speeds FDA review, REDEMPLO launch traction—read key insights.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...